Skip to content
Back to outputs

Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression

Research output: Contribution to journalArticlepeer-review

Standard

Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression. / Cambiano, V.; Lampe, F. C.; Rodger, A. J.; Smith, C. J.; Geretti, A. M.; Lodwick, R. K.; Holloway, J.; Johnson, M.; Phillips, A. N.

In: HIV Medicine, Vol. 11, No. 3, 01.03.2010, p. 216-224.

Research output: Contribution to journalArticlepeer-review

Harvard

Cambiano, V, Lampe, FC, Rodger, AJ, Smith, CJ, Geretti, AM, Lodwick, RK, Holloway, J, Johnson, M & Phillips, AN 2010, 'Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression', HIV Medicine, vol. 11, no. 3, pp. 216-224. https://doi.org/10.1111/j.1468-1293.2009.00771.x

APA

Cambiano, V., Lampe, F. C., Rodger, A. J., Smith, C. J., Geretti, A. M., Lodwick, R. K., Holloway, J., Johnson, M., & Phillips, A. N. (2010). Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression. HIV Medicine, 11(3), 216-224. https://doi.org/10.1111/j.1468-1293.2009.00771.x

Vancouver

Author

Cambiano, V. ; Lampe, F. C. ; Rodger, A. J. ; Smith, C. J. ; Geretti, A. M. ; Lodwick, R. K. ; Holloway, J. ; Johnson, M. ; Phillips, A. N. / Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression. In: HIV Medicine. 2010 ; Vol. 11, No. 3. pp. 216-224.

Bibtex

@article{a5fde8fff8ee4a349afdfcd9de545698,
title = "Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression",
abstract = "Objective: The aim of the study was to assess whether a simple, routinely available measure of antiretroviral therapy (ART) adherence predicts viral rebound at the next HIV viral load (VL) measurement in virally suppressed patients. Methods: The analysis was performed on the Royal Free HIV Cohort, London, UK. Each 'drug coverage-viral load episode' (DCVL episode) was defined as a 6-month period immediately prior to a VL ≤50 HIV-1 RNA copies/mL (time-zero), during which the patient had been continuously on HAART, with all measured VLs ≤50 copies/mL. The next VL after time-zero was used to assess whether VL rebound (defined as >200 copies/mL) had occurred. Drug coverage, our measure of adherence, was calculated as the proportion of days in the 6-month period covered by a valid prescription for at least three antiretroviral drugs. Results: A total of 376 (2.4%) VL rebounds occurred in 15 660 DCVL episodes among 1632 patients. Drug coverage was 100% for 32% of episodes, 95-99% for 16% of episodes and ≤60% for 10% of episodes. The risk ratio of rebound associated with a 10% increase in drug coverage, adjusted for potential confounding variables, was 0.93 (95% confidence interval 0.88-0.98). Conclusions: Antiretroviral drug coverage assessed at the time of VL measurement in patients with undetectable VL is potentially clinically useful for predicting VL rebound at the next VL measurement.",
keywords = "Antiretroviral drugs, Drug adherence, HIV infection, Prescription, Viral rebound",
author = "V. Cambiano and Lampe, {F. C.} and Rodger, {A. J.} and Smith, {C. J.} and Geretti, {A. M.} and Lodwick, {R. K.} and J. Holloway and M. Johnson and Phillips, {A. N.}",
year = "2010",
month = mar,
day = "1",
doi = "10.1111/j.1468-1293.2009.00771.x",
language = "English",
volume = "11",
pages = "216--224",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "BioMed Central",
number = "3",

}

RIS

TY - JOUR

T1 - Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression

AU - Cambiano, V.

AU - Lampe, F. C.

AU - Rodger, A. J.

AU - Smith, C. J.

AU - Geretti, A. M.

AU - Lodwick, R. K.

AU - Holloway, J.

AU - Johnson, M.

AU - Phillips, A. N.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Objective: The aim of the study was to assess whether a simple, routinely available measure of antiretroviral therapy (ART) adherence predicts viral rebound at the next HIV viral load (VL) measurement in virally suppressed patients. Methods: The analysis was performed on the Royal Free HIV Cohort, London, UK. Each 'drug coverage-viral load episode' (DCVL episode) was defined as a 6-month period immediately prior to a VL ≤50 HIV-1 RNA copies/mL (time-zero), during which the patient had been continuously on HAART, with all measured VLs ≤50 copies/mL. The next VL after time-zero was used to assess whether VL rebound (defined as >200 copies/mL) had occurred. Drug coverage, our measure of adherence, was calculated as the proportion of days in the 6-month period covered by a valid prescription for at least three antiretroviral drugs. Results: A total of 376 (2.4%) VL rebounds occurred in 15 660 DCVL episodes among 1632 patients. Drug coverage was 100% for 32% of episodes, 95-99% for 16% of episodes and ≤60% for 10% of episodes. The risk ratio of rebound associated with a 10% increase in drug coverage, adjusted for potential confounding variables, was 0.93 (95% confidence interval 0.88-0.98). Conclusions: Antiretroviral drug coverage assessed at the time of VL measurement in patients with undetectable VL is potentially clinically useful for predicting VL rebound at the next VL measurement.

AB - Objective: The aim of the study was to assess whether a simple, routinely available measure of antiretroviral therapy (ART) adherence predicts viral rebound at the next HIV viral load (VL) measurement in virally suppressed patients. Methods: The analysis was performed on the Royal Free HIV Cohort, London, UK. Each 'drug coverage-viral load episode' (DCVL episode) was defined as a 6-month period immediately prior to a VL ≤50 HIV-1 RNA copies/mL (time-zero), during which the patient had been continuously on HAART, with all measured VLs ≤50 copies/mL. The next VL after time-zero was used to assess whether VL rebound (defined as >200 copies/mL) had occurred. Drug coverage, our measure of adherence, was calculated as the proportion of days in the 6-month period covered by a valid prescription for at least three antiretroviral drugs. Results: A total of 376 (2.4%) VL rebounds occurred in 15 660 DCVL episodes among 1632 patients. Drug coverage was 100% for 32% of episodes, 95-99% for 16% of episodes and ≤60% for 10% of episodes. The risk ratio of rebound associated with a 10% increase in drug coverage, adjusted for potential confounding variables, was 0.93 (95% confidence interval 0.88-0.98). Conclusions: Antiretroviral drug coverage assessed at the time of VL measurement in patients with undetectable VL is potentially clinically useful for predicting VL rebound at the next VL measurement.

KW - Antiretroviral drugs

KW - Drug adherence

KW - HIV infection

KW - Prescription

KW - Viral rebound

UR - http://www.scopus.com/inward/record.url?scp=75649152847&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1293.2009.00771.x

DO - 10.1111/j.1468-1293.2009.00771.x

M3 - Article

C2 - 20002781

AN - SCOPUS:75649152847

VL - 11

SP - 216

EP - 224

JO - BMC Medicine

JF - BMC Medicine

SN - 1741-7015

IS - 3

ER -

ID: 10950063